318. New insights into respiratory infections in children

P2946 National surveillance of paediatric empyema in the UK; the UK-ESPE study
David Spencer1, Matthew Thomas1, Elemraid Mohammed1, Julia Clark1, Steve Howitt2, Odd Garred3,4,5
1Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom; 2School of Biology, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 3Clinical Sciences, Glasgow University, Glasgow, United Kingdom

UK-ESPE monitors the changing empyema epidemiology and compares manage- ment across the UK. Demographic, clinical and microbiological data on children undergoing pleural drainage were obtained from 19 paediatric respiratory cen- tres from September 2006-March 2011. Culture negative pleural fluid underwent pneumococcal PCR, positive samples were serotyped using an assay detecting 14 serotypes/groups. Robust multivariable survival models were used to analyse length of stay (LOS). Chi-squared, Kruskal-Wallis and Fisher’s test were used for other analyses. Data on 635 children were obtained (56% male, median age 4.3 years). If a bacterial cause was found (n=287), Streptococcus pneumoniae accounted for 68%, Staphylococcus aureus 14% and Staphylococcus aureus 4%. A pneumococ- cal serotype was detected in 125 patients with serotype (1/4/6), 3/22, 7,(12%) and 19A(9%). PCV-7 serotypes accounted for 48% in 2006/07 but had disappeared by 2010/11. Non-PCV7 serotypes increased over the same period. 19A was associ- ated with severe disease and the only reported death. Median tertiary LOS was 8 days (range 3-33) and median total hospital stay (THS) 11 days (range 5-43). Surgery was associated with a decrease in tertiary LOS of 41% (95% C.I.7-88%, p=0.01) and THS 11 days (range 5-43). In the secondary analyses. Data on 635 children were obtained (56% male, median age 4.3 years). If a bacterial cause was found (n=287), Streptococcus pneumoniae accounted for 68%, Staphylococcus aureus 14% and Staphylococcus aureus 4%. A pneumococcal serotype was detected in 125 patients with serotype (1/4/6), 3/22, 7,(12%) and 19A(9%). PCV-7 serotypes accounted for 48% in 2006/07 but had disappeared by 2010/11. Non-PCV7 serotypes increased over the same period. 19A was associated with severe disease and the only reported death. Median tertiary LOS was 8 days (range 3-33) and median total hospital stay (THS) 11 days (range 5-43). Surgery was associated with a decrease in tertiary LOS of 41% (95% CI 7-88%, p=0.015) and THS of 43% (95% CI 7-92%, p=0.015) compared to non-surgical treatment. This effect did not achieve significance when each treatment group was analysed separately. Empyema in the UK remains predominantly a pneumococcal disease with causative serotypes changing over time. Continuing surveillance is required to monitor changes following introduction of new pneumococcal vac- cines. Primary surgical strategies were associated with reduced hospital stay in this cohort.

P2947 Joint effects of smoking during pregnancy and polymorphisms in the MBL2 gene on cord blood levels of mannose-binding lectin
Oliver Fuchs1,2,3, Claire Jackson1, Peter Lackie1, Rob Howlin1,2,3
1Primary Ciliary Dyskinesia Research Group, Mater Children’s Hospital, Sydney, Australia; 2Paediatric Critical Care Research Group, Mater Children’s Hospital, Brisbane, Australia; 3Department of Paediatrics, University of Sydney, Sydney, Australia

Smoking in pregnancy may affect the developing immune system and is asso- ciated with respiratory disease in the offspring. Also levels of mannose-binding lectin (MBL), a soluble innate immune mediator, are related to early respira- tory morbidity. Yet, a joint effect of smoking in pregnancy and single-nucleotide polymorphisms (SNPs) in the MBL2 gene on MBL levels in cord blood (CB) is unknown.

MBL was measured in CB in N=221 participants of a birth cohort of unselected, healthy, term infants and dichotomized using cutoffs of 700 and additionally of 300 ng/ml. We studied the association of smoking in pregnancy (validated by cotinine levels in the first urine) with MBL levels in CB. Using the Illumina® HumanOmniExpress chip for genotyping, we assessed the association of MBL2 SNPs and of SNPs on a genome-wide basis with MBL levels. We explored effect modification by smoking adjusting for multiple testing and confounders. Smoking in pregnancy was significantly associated with lower MBL levels for both cutoffs of 700 and 300 ng/ml with an OR (95% CI) of 3.30 (1.73:6.29) and 2.99 (1.43:6.28), respectively. Several MBL2 SNPs were significantly associated with decreased MBL levels (lowest p=0.08 x 10^-17). On a genome-wide basis, no region other than MBL2 reached genome-wide significance. We found significant gene-environment interaction of MBL2 SNPs with smoking in pregnancy, such as for the downstream SNPs rs10824787 and rs3821968 (pmm=0.036 and pmm=0.044, respectively). Smoking during pregnancy lowers MBL levels in CB alone and in a joint effect with MBL2 SNPs. Our results may explain a link between genetic and environmental effects on early respiratory morbidity.

P2948 Inhaled racemic adrenaline versus saline in acute bronchiolitis, a multicenter randomized double-blind clinical trial
Håvard Ove Skjerven1,2, Jon Olav Gjengset Hunderli2, Sabine Kristin Brügmann-Pieper1, André Charlotte Brunn1, Kais-Håkon Carlsen1,2, Hanne Engen2, Leif Eksedal2, Marius Høifødt2, Jonas Lunde2, Peter Mowinckel1, Leif Bjarte Rolfjord1, Christian Siva2, Truls Vik6, Karin C. Ledup Carlsen1,2, 1Dept of Paediatric Medicine, Oslo University Hospital, Oslo, Norway; 2Dept of Paediatric Medicine, Tønsberg Hospital, Tønsberg, Norway; 3Dept of Paediatric Medicine, Telemark Hospital, Kragerø, Norway; 4Dept of Paediatric Medicine, Vestre Viken HF, Drammen, Buskerud, Norway; 5Dept of Paediatric Medicine, Vestfold Hospital, Tønsberg, Vestfold, Norway; 3Dept of Paediatric Medicine, Telemark Hospital HF, Skien, Telemark, Norway; 2Dept of Paediatric Medicine, Inlandet Hospital HF, Etterum, Hedmark, Norway; 1Dept of Paediatric Medicine, Inlandet Hospital, Lillehammer, Oppland, Norway; 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Background: The efficacy of inhaled racemic adrenaline (IRA) versus general supportive therapy in acute bronchiolitis in infants is questioned.

Aims: To assess efficacy of IRA versus inhaled saline and regular vs. on demand therapy in hospitalized infants with acute bronchiolitis

Subjects and methods: A multicenter (n=89) randomized double-blind controlled trial (pharmaceutical company independent) of IRA vs saline further randomised into regular vs on demand inhalations (up to every second hour) included 404 children < 12 months of age (mean 4.2 months), 29.9% boys, with moderate to severe acute bronchiolitis in Norway in 2009-11. A validated clinical score (0-10, 0 best) was used pre-and post inhalation daily. Inclusion required a score ≥ 4. Supportive therapy (oxygen, naegogastric feeding (NGF) or ventilatory support) were recorded. The primary outcome was length of stay (LOS) (hours until deemed ready for discharge). Analyses were by intention to treat except for LOS.

Results: Infants treated with IRA vs saline had no significant difference in LOS (mean, 95% conf interval) (59.6, 52.2-67.0 vs 63.8, 56.0-71.6), need for oxygen (21.8% vs 24.4%), ventilatory support (7.4 vs 7.5%), supportive treat- ment (27.2 vs 25.9%) or relative improvement in clinical score from pre-inhalation (0.25 vs 0.22) (all p>0.1). As expected, fewer patients inhaled more medication indica- tions in shorter mean LOS (54.9, 47.9-62.0 vs 68.1, 60.4-75.7 hrs, p= 0.01) and fewer inhalations (11.9 vs 17.0) (p<0.001).

Conclusion: Inhaled RA for acute bronchiolitis is not more effective than inhaled saline, whereas inhalations on-demand appears more effective than regular intervals.

P2949 Is primary ciliary dyskinesia a “biofilm” disease?
Becky Walker1,2,3, Claire Jackson1, Peter Lackie1, Rob Howlin1,2,3, Allan Ray2,3, Faust Saul2,3, Jane Lucas1,2,3, Luanne Hall-Stoodley2,3
1Primary Ciliary Dyskinesia Research Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom; 2NIHR Wellcome Trust Clinical Research Facilities, University of Southampton and University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom; 3Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, United Kingdom

Introduction: Bacterial biofilms are structured communities of adherent bacteria enveloped in self-produced matrix which are refractory to antibiotics and the host immunity response. They play a key role in the chronology of respiratory infection in cystic fibrosis. Haemophilus influenzae is the most common pathogen isolated in primary ciliary dyskinesia (PCD). We hypothesise that impaired mucociliary clearance in PCD will predispose these patients to biofilm infections.

Aims: To investigate the biofilm-forming capacity of clinical H. influenzae isolates from PCD patients.

Methods: The biofilm-forming ability of 4 H. influenzae clinical isolates from different PCD patients were compared using a crystal violet (CV) assay, colony forming unit counts (CFUs), fluorescence in situ hybridisation (FISH) and scanning electron microscopy (SEM).

Results: CV staining demonstrated bacterial biomass adherent to plastic for all isolates (OD600 0.04 for isolate 1 to 0.12 for isolate 4, p<0.05). SEM permitted visualisation of a characteristic matrix surrounding the bacteria. Biofilm thickness varied for each isolate, qualified by FISH (13 μm for isolate 1, 82 μm for isolate 4). CFU quantified the number of viable bacteria within each day 4 biofilm, ranging from 9x10^6 CFU/cm^2 in isolate 1 to 2x10^7 CFU/cm^2 in isolate 4.
Conclusion: We have characterised biofilm-forming capacity in all 4 *H. influenzae* isolates from PCD patients. 2 isolates from chronically colonised patients (over 4 years) consistently formed thicker, cell dense and structurally more complex biofilms than the other, more recently isolated, strains. These data suggest that *H. influenzae* is capable of biofilm formation and that PCD patients, like cystic fibrosis, might harbour bacteria in biofilms.

P2950 Evidence of increased pathogenicity of HRVC compared with HRVA and B: Comparisons between children with an acute lower respiratory illness and controls

Davide Cacciarelli1,2, Siew-Kim Khor3, Giovanni Ferrari2, Guicheng Zhang2, Wai-Ming Lee2, Gary Geelhoed2, Jack Goldblatt3, James Gemm2, Joellene Bizzintino2,3, Ingrid Laing2,3, Peter Le Souef1,2.

**Background:** Recent studies suggest that human rhinovirus group C (HRVC) is more pathogenic in young children than HRVA and B. However, the relative frequency of isolation of these HRV groups between children presenting to an emergency department (ED) with an acute lower respiratory illness (ALRI) and healthy community controls has not been determined.

**Aims:** To compare isolation rates for HRVA, B and C between children with an ALRI presenting to ED and health community controls.

**Methods:** Children aged 0-5 years presenting with an ALRI to the ED of a tertiary paediatric hospital along with healthy children selected from a local childcare centre were prospectively recruited. A nasal sample was collected at recruitment from which RNA was extracted and reverse transcribed. From cDNA, a 2-step PCR of the HRV 5' NCR was used for HRV detection and molecular typing.

**Results:** There were no differences in isolation rates for HRVA between ALRI cases and controls. Isolation rates for HRVB were low and slightly higher in controls than cases. For HRVC, not only were isolation rates higher than for HRVA or HB, but rates were substantially higher for cases versus controls (48.5 vs 8.7%; p<0.001).

**Conclusions:** HRVC is the most common HRV group causing ALRI in this group of young children, but is relatively uncommon in healthy children. In contrast, HRVA and HB were not more common in children with ALRI than controls. These data provide support for HRVC being more pathogenic than HRVA and B.

P2951 RSV hospitalization in Down syndrome in the Canadian Registry of Synaxis (CARESS) following prophylaxis (2006-2011)

Ian Le3,4,5, Bosco Paes2, Abby Li3, Krista Lanctot3.

1Pediatria, University of Calgary, AB, Canada; 2Pediatria, McMaster University, Hamilton, ON, Canada; 3Sunnybrook Hospital, University of Toronto, ON, Canada

**Background:** The Canadian Registry of Synaxis (CARESS) tracks palivizumab use and RSV hospitalizations including 299 full term Down syndrome (DS) infants without congenital heart disease.

**Objective:** To determine respiratory illness (RII) and RSV hospitalization (RSHV) rates in healthy DS infants who received palivizumab compared to: 1) infants with underlying medical disorders (MD) and 2) infants who meet standard indications for RSV prophylaxis (SD).

**Design/Methods:** A prospective, observational, registry of infants who received 1 dose of palivizumab during the 2006-2011 RSV seasons. Data collected monthly.

**Results:** 10.061 infants were enrolled (DS: 299; 3.0%; infants with MD: 1247, 12.4%; and SD: 845, 8.6%). Participants were significantly different (p<0.005) in most demographic variables and risk factors such as siblings, smoke exposure, ≥ 5 household members and daycare attendance. Compliance rates relative inter-dose intervals (p<0.025) across the groups was similar, though the DS group received a significantly higher proportion of their expected injections (p<0.018). A significantly greater proportion of DS had RIs compared to MD (p<0.025), but not SD infants. DS infants did not have a significantly different RSHV rate (1.18%) from either MD (2.55%; p=0.627) or SD (1.52%; p=0.547).

**Conclusions:** Rates of hospitalization for respiratory illnesses and RSV-related hospitalization did not differ among the groups following prophylaxis. Palivizumab may be efficacious in reducing RSHV in DS compared to reported historical un-treated controls in a similar Danish cohort of DS patients (untreated; 7.6%; versus treated; 1.6%; 77% reduction).

P2952 Role of probiotics in attenuation of acute respiratory tract infections in preschool and primary school children

Sergei Gerasimov1, Orya Cury2.

1Pediatrics, Lviv National Medical University, Lviv, Ukraine; 2Pediatrics, Ivanovo-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

**Background:** Probiotics have been shown to reduce incidence, duration and symptom scores of acute respiratory tract infections (ARTI).

**Objective:** To study a potential of probiotics in prevention of ARTI in children.

**Materials and Methods:** 96 otherwise healthy children aged 3-12 years closely contacted to a household with ARTI were randomized to receive 1 g of a powder containing 5 billion CFU of *L. acidophilus* DDS-1, *B. lactis* and 50 mg fructooligosaccharide (DDS Junior, UAS Laboratories) (group I, n=48) or rice maltodextrine powder (group II, n=48) once daily for 30 days. During one-month follow-up, we recorded incidence, duration, and clinical course of ARTI using Canadian acute respiratory illness and the scale (CARIS).

**Results:** At baseline groups I and II were comparable on age, number of social contacts, history of attending daycare/school, and history of previous ARTI. 85% (41/48) of children in the group I and 90.9% (44/49) in the group II developed ARTI (p=0.368). In sick children at group I 50% clinical recovery from baseline value of CARIS occurred on day 6.2(1.9), while in the group II on day 7.2(2.1) (p=0.025). For the group I return to normal health was observed on day 8.5(3.3) vs 10(7.3) in the group II (p=0.007). In the group I nasal decongestants, throat preparations, and antipyretics were used for a shorter course than in the group II (2.5(1.2) vs 3.2(1.7) p=0.007; 1.9(1.1) vs 2.9(1.0) p=0.046; 2.7(1.2) vs 3.5(1.5) p=0.089, respectively.

**Conclusions:** At tendency toward prophylactic potential in limitation of household spread, probiotics have a clear attenuating effect on the clinical course of ARTI in young children and shorten use of flu/cold drugs.

P2953 Active cytomegalovirus infection in non-immunosuppressed children with chronic respiratory disease

Maria Teresa Romero Rubo1, David Navarro Ortega1, Raquel Lucas Sendra1, Jordi Miret1, Maria Chilet Saez2,3, Amparo Escoballino Montans2.

1Pediatric Pulmonology, Hospital de Denia, Alicante, Spain; 2Department of Microbiology, Hospital Clinico Universitario. Universidad de Valencia, Valencia, Spain; 3Pediatric Pulmonology, Hospital Clinico Universitario, Valencia, Spain; 4Department of Microbiology, Hospital Clinico Universitario, Valencia, Spain; 5Pediatric Pulmonology, Hospital Clinico Universitario. Universidad de Valencia, Valencia, Spain

**Cytomegalovirus (CMV) is reactivated in lower respiratory tract in the context of local or systemic inflammatory processes, increasing its morbimortality.**

**Objective:** To set the incidence of acute CMV infection in children with chronic respiratory diseases and no acute exacerbation.

**Material and methods:** Mixed retrospective-prospective study (May 2009-September 2011) of non-immunosuppressed children who underwent a diagnostic bronchoscopy. The serological test for the CMV was performed using CLIA (DiAsorin, Italy). Detection and quantification of DNA in respiratory samples and plasma by PCR QRT-PCR in the m2000RT system (AbbottDiagnostics, USA).

**Results:** 36 patients (45.5 male; mean age 5.5 years. Underlying diseases were cystic fibrosis(10), middle lobe syndrome (6), laryngotracheomalacia(4), poorly controlled asthma (3), obliterans bronchiolitis (2), interstitial lung disease (2); tracheostomy complications (2); bronchiectasis (2); persistent atelectasis (2); bronchial sequelae after bronchial tuberculosis (1); pulmonary hypoplasia (1) and pulmonary hemosiderosis (1). 11 patients were IgG positive CMV DNA detected in 6 respiratory samples (16.6%); 54.5% of the IgG positive population, 4 in bronchoalveolar lavage and 2 in bronchoaspirated. Viral DNA detected in plasma in two of them. The mean viral load at respiratory samples was 180 copies/mL (range 27-815 copies/mL) and in plasma 18 and 123 copies/mL. All the positive CMV children were under inhaled corticosteroid treatment.

**Conclusion:** Active CMV infection is common in non-immunosuppressed children with chronic respiratory disease. Prospective studies should elucidate the effects of CMV replication in their lower respiratory tract and clinical evolution.

P2954 The microbiology of lung disease in ataxia telangiectasia (A-T)

Jayesh Bhatt, Andrew Bush. UK National Ataxia Telangiectasia Clinic, Nottingham Children’s Hospital, Nottingham, Notts, United Kingdom UK National Ataxia Telangiectasia Clinic, Nottingham, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

**Background:** A-T is a progressive, neurodegenerative disease causing immunodeficiency, an increased risk of malignancy & respiratory system complications, like chronic sinusopulmonary disease, bronchiecitis, interstitial lung disease & aspiration. The high early age mortality is due to cancer & respiratory disease. Little is known about what causes lung infections in A-T (Ped Pul 2010;45:847-59).

**Aim:** To describe the microbiology of Respiratory tract in patients attending the UK National A-T clinic in order to guide blind antimicrobial therapy, & to inform future studies to improve the evidence base for A-T treatment.

**Methods:** We prospectively obtained cough swabs or sputum cultures as age-
appropriate & throat swabs for virology. We collected data on new treatment prescribed, current maintenance antibiotic or immune replacement therapy.

Results: 56 children (68% consults) were seen in the clinic (May 09 to January 12). We could not obtain a sample in some children (Bacteria, n=14; Viruses, n=33).

Table 1. Microbiology

<table>
<thead>
<tr>
<th>Viruses (n=55 consults)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhinovirus 10</td>
<td>175 children (5.65 ± 1 years) with ≥ CAP</td>
</tr>
<tr>
<td>Metapneumovirus 1</td>
<td>20.7% of patients with CAP and A, with pulmonary fibrosis (PF) in 48.3% of this group of patients. 26.7% of children with PH and PF had CT evidence of emphysematous bullae (EB). Patients with CAP and A received antibiotic treatment (macrolides) (ABT) besides controller therapy for achievement of A control.</td>
</tr>
<tr>
<td>No Resp. viruses 24</td>
<td>Conclusions: Our findings are similar to previous series (n=15) (Acta Pedital 2007;96:1021–24) but with no opportunistic infections; bacterial infection is common and current management is based on extrapolation from other lung conditions. A-T specific evidence based guidelines are urgently needed.</td>
</tr>
<tr>
<td>Resp. commensals 47</td>
<td>Background: The prevalence of heritable connective tissue disorders (HCTD) changed manifestations of community-acquired pneumonia (CAP) in pediatric patients, leading to diagnostic and therapeutic errors.</td>
</tr>
<tr>
<td>H. influenzae 3</td>
<td>Objective: To study clinical features of CAP in children with HCTD.</td>
</tr>
<tr>
<td>Metapneumovirus 1</td>
<td>Material and methods: 105 patients aged 3–18 years, with clinically, serologically and radiographically diagnosed CAP were followed up for two years. 45% of patients had moderate persistent asthma (A). All pediatric patients had HCTD manifestations.</td>
</tr>
<tr>
<td>P. aeruginosa 2</td>
<td>Results: CAP caused by Mycoplasma pneumonia (Mp) was in 89.1% of patients, by Cytomegalovirus (Cmv) - in 26.7%, by Chlamydomphilus pneumonia (Cmv) - in 31%.</td>
</tr>
<tr>
<td>B. cepacia 1</td>
<td>We observed a significant modulation in growth below 12.5 mM acetate (p &lt; 0.05). We detected SCFAs in the low millimolar range in the sputum of CF patients. SCFAs are more volatile at low pH values, and reports have shown that CF patient sputum is acidic. Recently, we detected SCFAs in the low millimolar range in the sputum of CF patients.</td>
</tr>
</tbody>
</table>

Table 2. Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/56 children (12.5%)</td>
</tr>
<tr>
<td>15/58 (22%) consults (n=5 Intravenous, n=8 oral, n=2 nebulled &amp; oral)</td>
</tr>
<tr>
<td>41/56 children (73%)</td>
</tr>
</tbody>
</table>

Conclusions: Our findings are similar to previous series (n=15) (Acta Pedital 2007;96:1021–24) but with no opportunistic infections; bacterial infection is common and current management is based on extrapolation from other lung conditions. A-T specific evidence based guidelines are urgently needed. 

P2955

Community-acquired pneumonia in pediatric patients with heritable connective tissue disorders: Novel phenotypic variants

Zoa Nesterenko1, Olena Ivanina2, Department of Pediatrics, SI “Lugansk State Medical University”, Lugansk, Ukraine; 3Polyclinic Department, Lugansk Municipal Children’s Hospital #2, Lugansk, Ukraine

Background: The prevalence of heritable connective tissue disorders (HCTD) changed manifestations of community-acquired pneumonia (CAP) in pediatric patients, leading to diagnostic and therapeutic errors.

Objective: To study clinical features of CAP in children with HCTD.

Material and methods: 105 patients aged 3–18 years, with clinically, serologically and radiographically diagnosed CAP were followed up for two years. 45% of patients had moderate persistent asthma (A). All pediatric patients had HCTD manifestations.

Results: CAP caused by Mycoplasma pneumonia (Mp) was in 89.1% of patients, by Cytomegalovirus (Cmv) - in 26.7%, by Chlamydomphilus pneumonia (Cmv) - in 31%. |

Conclusions: Our findings are similar to previous series (n=15) (Acta Pedital 2007;96:1021–24) but with no opportunistic infections; bacterial infection is common and current management is based on extrapolation from other lung conditions. A-T specific evidence based guidelines are urgently needed. 

P2956

Effect of short-chain fatty acids and pH on aerobic and anaerobic growth of Pseudomonas aeruginosa

Peyman Ghobadi1, Prisilla Santhakumar2, Nades Palaniyam1,2,3

Background: Pseudomonas aeruginosa (PA) is one of the most common pathogens in patients with cystic fibrosis (CF) lung disease. PA and other anaerobic bacteria produce short-chain fatty acids (SCFAs) as byproducts of anaerobic fermentation.

Methods: In double-blind, placebo-controlled study, 175 children (5.65 ± 1 years) with ≥ CAP, A and HCTD, 48.3% of patients had moderate persistent asthma (A). All pediatric patients had HCTD manifestations.

Results: CAP caused by Mycoplasma pneumonia (Mp) was in 89.1% of patients, by Cytomegalovirus (Cmv) - in 26.7%, by Chlamydomphilus pneumonia (Cmv) - in 31%. |

Conclusions: Our findings are similar to previous series (n=15) (Acta Pedital 2007;96:1021–24) but with no opportunistic infections; bacterial infection is common and current management is based on extrapolation from other lung conditions. A-T specific evidence based guidelines are urgently needed. 

P2958

Modulation effect of beta-glucan isolated from Pleurotus ostreatus in children with recurrent respiratory tract infections

Milos Jesenak1, Peter Banocvic1, Juraj Majtan2, Zuzana Rennerova1,2

Background: The prevalence of heritable connective tissue disorders (HCTD) changed manifestations of community-acquired pneumonia (CAP) in pediatric patients, leading to diagnostic and therapeutic errors.

Objective: To determine if SCFAs affect bacterial growth at different pH levels.

Methods: The laboratory strain PA01 and a clinical isolate PA058 were used for experiments with and without the addition of SCFAs (acetate, propionate, butyrate) at a range of concentrations between 3.125-100 mM and pH values from 5.5-7.0 in tryptic soy broth. Optical density at 600 nm was measured every 30 minutes for a 6 hour period, as well as viable colony counts after the period of incubation. Anaerobic/microaerobic conditions were generated by sealing microplates with optically-clear PCR film. 

Results: Acetate showed a significant inhibition in growth above 50 mM (p < 0.001) that was dependent on pH. Conversely there was a significant increase in growth below 12.5 mM acetate (-20%, p < 0.05). Propionate had the highest inhibition, followed by butyrate and acetate. Anaerobic conditions resulted in lower growth overall and showed similar trends in growth inhibition. Results were consistent for both PA strains tested.

Conclusions: SCFAs increase the growth of laboratory and clinical strains of PA at concentrations found in CF patient sputum, but inhibit growth at high concentrations. SCFAs produced by anaerobic bacteria may provide an indication of increased virulence of PA.
Longitudinal microbiology of children with primary ciliary dyskinesia

Monique Walker1,2, Claire Jackson1,2, Amanda Harris1, Samantha Packham1, Jane Lucas1,2.
1Primary Ciliary Dyskinesia Research Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom; 2Primary Ciliary Dyskinesia Diagnostic Service, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Introduction: Longitudinal changes in the respiratory microbiology of cystic fibrosis is well characterised; Staphylococcus aureus & Haemophilus influenzae are initially isolated before chronic Pseudomonas aeruginosa colonisation. However there is a paucity of similar microbiological data for primary ciliary dyskinesia (PCD).

Aims: Longitudinal assessment of respiratory microbiology in paediatric PCD patients in a UK specialist centre.

Methods: Results of sputum and cough swab microbiology from PCD patients (aged 2.1-19.3 years old, n=17) between January 2003–January 2012, were reviewed. Results were divided into 5-year cohorts corresponding to patient age at time of sample acquisition (Table 1).

Results: 168/341 (49.1%) cultures were positive. H. influenzae was most prevalent (61/168, 36.3%) followed by S. aureus (32/168, 19%), Streptococcus pneumoniae (27/168, 16%) and P. aeruginosa (16/168, 9.5%). The predominance of H. influenzae continued throughout childhood apart from in 5-10 year olds where there were equivalent numbers of H. influenzae, P. aeruginosa, S. aureus & S. pneumoniae (Table 1).

Conclusion: H. influenzae is the predominant pathogen in our PCD patients throughout childhood, particularly >10 years old. The progression to chronic P. aeruginosa colonization seen in CF is not evident in our PCD population.

Table 1. Percentage prevalence of bacteria in PCD children in a tertiary follow up clinic in the UK (overall and in age bands)

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Overall (n=168)</th>
<th>0-5 yrs (n=28)</th>
<th>5–10 yrs (n=67)</th>
<th>10–15 yrs (n=47)</th>
<th>15–20 yrs (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. influenzae</td>
<td>36 (28.1%)</td>
<td>32 (11.4%)</td>
<td>18 (26.8%)</td>
<td>55 (57.1%)</td>
<td>54 (80.8%)</td>
</tr>
<tr>
<td>S. aureus</td>
<td>19 (11.3%)</td>
<td>15 (5.3%)</td>
<td>22 (32.8%)</td>
<td>21 (33.8%)</td>
<td>11 (20.8%)</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>16 (9.7%)</td>
<td>11 (3.9%)</td>
<td>24 (35.6%)</td>
<td>13 (26%)</td>
<td>8 (19.2%)</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>10 (6.0%)</td>
<td>7 (2.5%)</td>
<td>19 (28.4%)</td>
<td>0 (0%)</td>
<td>4 (7.7%)</td>
</tr>
<tr>
<td>M. catarrhalis</td>
<td>3 (1.8%)</td>
<td>2 (0.7%)</td>
<td>5 (7.4%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Fungi and yeast</td>
<td>7 (4.2%)</td>
<td>14 (5.0%)</td>
<td>6 (8.8%)</td>
<td>0 (0%)</td>
<td>15 (23.1%)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (5.4%)</td>
<td>14 (5.0%)</td>
<td>6 (8.8%)</td>
<td>11 (23.4%)</td>
<td>8 (15.4%)</td>
</tr>
</tbody>
</table>